About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Trial to Assess the Antipsychotic Efficacy of ITI-007

NCT02282761·11 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Intra-Cellular Therapies, Inc.

Age

18–60

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis of schizophrenia
experiencing an acute exacerbation of psychosis

You may not be if

any subject unable to provide informed consent
any female subject who is pregnant or breast-feeding
any subject judged to be medically inappropriate for study participation

The record

StatusCompleted

PhasePhase 3

Taking part450

StartedNov 2014

UpdatedOct 2, 2025

Conditions

Where11

Clinical Site
Little Rock, Arkansas, United States
Clinical Site
Springdale, Arkansas, United States
Clinical Site
Escondido, California, United States

Clareo Health | A Trial to Assess the Antipsychotic Efficacy of ITI-007